Form Type:  CT ORDER
Filing Date:  4/12/2012 
CIK:  0000881464 
Address:  9360 TOWNE CENTRE DR
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  (619) 552-2200 
Fiscal Year:  12/31 
Description of Business
We are a biopharmaceutical company committed to improving the lives of people with diabetes and other metabolic diseases through the discovery, development and commercialization of innovative medicines. We are marketing two first-in-class medicines to treat diabetes, BYETTA® (exenatide) injection and SYMLIN ® (pramlintide acetate) injection. We are also marketing the first and only once-weekly diabetes treatment, BYDUREON(TM) (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. In 2011 and early 2012, we executed on key initiatives for the company, including: * Obtaining approval for BYDUREON in the United States in January 2012 and the European Union in June 2011.
Register and access this filing in: